Peptides Have Arrived: HHS Won't Pursue Pharmacies Making Six of Them
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Since 2023, the answer to "can I get BPC-157 from a licensed pharmacy?" has been a qualified no. That shifted on October 28, when the federal health agency filed a draft policy saying it does not intend to act against a state-licensed pharmacy, a federal site or a licensed doctor that makes any of six named peptides, so long as ten terms are met (Federal Register). The six are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
This is the step the peptide world has waited on since July. It is also smaller than the headlines sound, and it is still a draft open for public comment. Here is what to know as you start to navigate peptides in the compounding space.
Who This Helps
This is for anyone following the peptide story, and for people who have been offered a peptide by a clinic or an online health company and want to know if it is above board now. It is also for people on a GLP-1 who keep seeing peptides sold next to their shot.
What the policy says
The text calls itself a draft, and comments are open through Nov. 13, 2026 (Federal Register). The policy is not binding "on HHS or the public," in its own words, and it does not change the law. NPR put the point plainly: it "doesn't change their legal status" (NPR). The notice also states that compounded drugs are not FDA-approved, and that the FDA does not check their safety, how well they work, or how good they are before they go on sale. Essentially, this is a move to decriminalize their compounding.
What it does is set out, for now, that HHS does not intend to act against pharmacies working with those six peptides listed. NPR called it the agency looking the other way for small pharmacies (NPR). The policy holds until a final rule settles each peptide, and HHS says it may revisit it if a safety signal or a product problem turns up.
Four limits matter here:
- It covers small pharmacies, not the big ones. The notice names state-licensed pharmacies, federal sites and licensed doctors. NPR and a compounding law alert both read that as leaving out the larger 503B outsourcing plants (NPR). Our 503A vs 503B guide explains the difference.
- You need a prescription. One requirement is a prescription written for you by name, so nothing here allows you to get a peptide without seeing a clinician first. An HHS aide told CNN the policy calls for a prescription in each patient's name, traced ingredients, lab testing and safety reports (CNN).
- One peptide per vial. The vial can hold just one listed active drug, which leaves out the "stacks" sold online (Drug Topics).
- Research-use-only vials are not covered. The policy only reaches licensed pharmacies, federal sites and doctors, so a vial from a research-chemical site sits where it sat last month. Its stated aim is to pull people away from research-use-only peptides shipped in from abroad.
The policy also ties each peptide to set forms (injection, pill, nasal spray, etc), so a pharmacy cannot make any version it likes. Which form goes with which peptide is a question for your prescriber and the pharmacy, not something to work out from a web page.
None of the six is approved
None of the six is an approved drug. An HHS aide told CNN that the policy "does not grant FDA approval or establish clinical safety and effectiveness" (CNN).
The evidence behind them is still thin, and that was the sticking point in July, when an FDA panel backed six of the seven peptides it looked at. The three we know the count for each passed 8 to 6, with one member sitting out. FDA staff had argued against easing the limits, and briefing papers called the studies they had, five of them on BPC-157, short, small and not enough to go on (AJMC). We covered that vote in FDA Panel Backs 6 Peptides for Compounding.
Reaction split. Public Citizen said the policy lets these products be made, sold and prescribed with no worry about federal action, and NPR reported the group's view that HHS went around the normal rulemaking process (NPR). The Partnership for Safe Medicines had filed a petition the week before, asking the FDA to set the July vote aside (NPR). The Alliance for Pharmacy Compounding, which speaks for compounders, welcomed it instead. It called the policy a more accountable alternative, one that brings patients into a system where pharmacy standards, oversight and safety reporting apply.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Supply will lag behind the headline
A policy statement is a good start, but for some being able to order peptides will take longer. This was a maybe, not a sure thing, right up to the filing, and it took many by surprise. Our own read of the market is that many clinics and online health companies had not lined up a pharmacy partner for peptides, because there was nothing yet to sign one for. The pharmacies are not ready to create these either, and that part is on the record.
The pharmacy trade group said it may take time before shops start filling orders (NPR). The firms that sell the raw drug have to meet the new testing and sourcing rules first, and pharmacies have to check that they did. One pharmacy owner told NPR his firm will not be able to meet demand. He expects to make just one of the six at first, and the plant is not ready at the time of statement. He doubted that all the small pharmacies in the country could keep up.
So expect a staggered rollout. Some providers will be ready sooner than others, some will quote a waitlist, and some will not prescribe at all. An ER doctor told Healio that saying no is a fair choice, since none of these are approved and there is no set dose or long-term safety data for any of them (Healio).
Two more notes. A peptide-industry figure told CNN that prices could climb substantially as demand rises (CNN). And compounded drugs generally sit outside pharmacy benefit coverage, so expect to pay out of pocket (AJMC).
Your state still gets a vote
The policy comes from the federal health agency. State boards license pharmacies and prescribers, and a federal policy does not bind them. Attorneys writing up the policy warn that nobody should assume state boards will take the same approach (Drug Topics). States have already split on peptides, so where you live may matter as much as the federal view.
How to stay safe while this settles
The policy does not make any of these peptides proven. What it offers is a paper trail: a named prescriber, a licensed pharmacy, a tested ingredient and a duty to report problems. A research-chemical site gives you none of that. The health questions stay open. If you are weighing one:
- Start with a clinician who has your full history, and get a real prescription. The policy only covers a vial made against a prescription written for you. Your clinician knows your other medicines, what you are treated for and, if you take one, your GLP-1. That is the person to judge whether a peptide belongs near your plan.
- See which pharmacy will fill it, and check that it is licensed in your state. Look the license up with your state board rather than taking the website's word for it. Our guide to what to check at checkout walks through the questions.
- Look up the prescriber too. Your state medical board shows the license and any action taken against it.
- Read reviews, and read the bad ones. What past patients say about shipping, answers to questions and what showed up in the box tells you more than the sales page.
- Skip anything sold as research use only. The policy does not cover those vials. One physician told AJMC that grey-market peptides often hold 5% to 75% of the amount on the label (AJMC). Our report on black-market peptide vials that didn't match their labels found vials both over and under what the label promised.
- Expect one drug in the vial, and ask what's in it. Blends or ‘stacks’ fall outside the policy, so a seller offering a stack is not working under it.
- Report problems. The policy tells pharmacies to report serious side effects and product problems, and the label has to show you how. You can also report straight to the FDA through MedWatch.
Final Takeaway
Peptides have arrived, with an asterisk. The federal health agency will not act against small pharmacies making six named peptides, so long as ten terms are met. That comes from a draft policy, still open for comment through Nov. 13. The law did not change, and none of the six is approved. HHS points to new ingredient-testing data and a record of past use; FDA staff called the clinical studies too small and short to go on. Supply will lag the headline, since ingredient sellers and pharmacies have work to do first, and our read is that many providers are still finding a partner pharmacy. If you are weighing one, the safe path looks like the one for a compounded GLP-1: a clinician with your full history, a real prescription, a pharmacy licensed in your state, and nothing from a research-chemical site.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Are peptides legal now?
The law did not change, but the federal health agency put out a draft policy saying it does not intend to act against state-licensed pharmacies, federal sites or licensed doctors that make six named peptides, so long as ten terms are met. The peptides are still unapproved, the draft is open for comment through Nov. 13, 2026, and it lasts only until a final rule settles each one.
Which peptides does the policy cover?
BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy ties each one to set forms, and a vial may hold just one of them, so stacks fall outside it. Peptides sold as research use only are not covered either.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
Some peptides are FDA-approved medicines and some "research" peptides are risky. A plain-language guide to telling safe sources from unsafe ones.
An Australian lab tested 18 vials sold as retatrutide. One matched its label. See what the dosing errors were and why a purity test proves little.
The White House logged an FDA peptide compounding policy on Oct 14. See what it could change, what's still not legal, and what to watch.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.